Replimune Group (NASDAQ:REPL) Announces Quarterly Earnings Results

Replimune Group (NASDAQ:REPL - Get Free Report) released its earnings results on Wednesday. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09), Zacks reports.

Replimune Group Trading Down 1.3 %

NASDAQ REPL traded down $0.19 during midday trading on Friday, hitting $14.10. The company had a trading volume of 431,744 shares, compared to its average volume of 790,791. Replimune Group has a twelve month low of $4.92 and a twelve month high of $17.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The firm has a 50-day moving average price of $12.54 and a 200-day moving average price of $11.73.

Insider Buying and Selling

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the sale, the chief executive officer now owns 202,014 shares of the company's stock, valued at $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. 8.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Jefferies Financial Group increased their target price on Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a report on Wednesday, December 4th. HC Wainwright raised their target price on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday. Finally, BMO Capital Markets raised their price objective on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 22nd. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $19.29.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.